New generation of drugs show early efficacy against drug-resistant TB
(Harvard Medical School) New drug regimen for multidrug-resistant tuberculosis shows early effectiveness in 85 percent of patients in a cohort including many with serious comorbidities. The results suggest a global need for expanded access to two recently developed medicines, bedaquiline and delamanid. Study cohort included many people who would have been excluded from trials because of comorbidities, severity of disease or extent of drug resistance. Findings highlight the importance of innovative regimens to improve outcomes for patients with multidrug-resistant tuberculosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Africa: MSF Welcomes Price Cut On Lifesaving TB Drug
[MSF] New York/Geneva -- The international medical humanitarian organization Doctors Without Borders/M édecins Sans Frontières (MSF) welcomes Johnson& Johnson's (J&J) announcement today to reduce the price of its tuberculosis (TB) drug bedaquiline to $1.50 per day. Governments must now urgently scale up the use of the treatment as a core part of drug-resistant TB (DR-TB) regimens, MSF said. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 7, 2020 Category: African Health Source Type: news

Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO ® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
GENEVA, SWITZERLAND, 6 JULY 2020 – The Stop TB Partnership and Johnson & Johnson – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income countries to rapidly scale up use of SIRTURO® (bedaquiline) 100mg tablets in support of new, recently-released World Health Organization (WHO) treatment guidelines. Effective immediately, Johnson & Johnson will make bedaquiline available to Stop TB Partnership’s Global Drug Facility (GDF) at a price of USD$340 per si...
Source: Johnson and Johnson - July 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves New Pediatric Formulation of Sirturo (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
NEW BRUNSWICK, NJ, May 27, 2020— The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of Sirturo (bedaquiline).... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 28, 2020 Category: Drugs & Pharmacology Source Type: news

U.S. FDA Approves New Pediatric Formulation of SIRTURO ® (bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received acceler...
Source: Johnson and Johnson - May 27, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

EMA Panel Backs Pretomanid for Drug-Resistant TB EMA Panel Backs Pretomanid for Drug-Resistant TB
Pretomanid FGK, in combination with bedaquiline and linezolid, is for adults with extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant tuberculosis.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 31, 2020 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
This research paper concludes that the combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 12, 2020 Category: Consumer Health News Source Type: news

New TB Drug Regimen Controls Resistant Disease in 9 of 10 Cases - Study New TB Drug Regimen Controls Resistant Disease in 9 of 10 Cases - Study
The new anti-tuberculosis drug combination of bedaquiline, pretomanid and linezolid cures 90% of people with deadly drug-resistant TB if given for six months, according to results published in the New England Journal of Medicine.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

New TB drug regimen controls resistant disease in 9 of 10 cases: study
(Reuters Health) - The new anti-tuberculosis drug combination of bedaquiline, pretomanid and linezolid cures 90% of people with deadly drug-resistant TB if given for six months, researchers report in The New England Journal of Medicine. (Source: Reuters: Health)
Source: Reuters: Health - March 5, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Africa: As J & J Releases Earnings, MSF Protests Price of Lifesaving TB Drug in Front of New York Stock Exchange
[MSF] New York -Doctors Without Borders/M édecins Sans Frontières (MSF) protested in front of the New York Stock Exchange in New York today, demanding the pharmaceutical corporation Johnson& Johnson (J&J) make the tuberculosis (TB) drug bedaquiline available for all people with drug-resistant TB (DR-TB) for no more than a dollar a day. The price of this crucial drug must be lowered to reflect the joint contributions made to its research and development by taxpayers and the global scientific and TB co (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 23, 2020 Category: African Health Source Type: news

World Health Organization Recommends the Use of Bedaquiline-Containing Treatment Regimens For All Drug-Resistant Tuberculosis Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 16, 2019 Category: Pharmaceuticals Source Type: news

Africa: Johnson & Johnson Must Halve Price of Lifesaving TB Drug Bedaquiline
[MSF] M édecins Sans Frontières (MSF) has launched a global campaign calling on pharmaceutical corporation Johnson& Johnson (J&J) to lower the price of its anti-tuberculosis medicine bedaquiline to no more than US$1 per day for people everywhere who need it, in order to allow scale-up of drug-resistant tuberculosis (DR-TB) treatment and reduce deaths. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 10, 2019 Category: African Health Source Type: news

FDA approves pretomanid tablets in combination with bedaquiline and linezolid for treatment of extensively drug resistant, treatment-intolerant or nonresponsive multidrug resistant pulmonary TB
Pretomanid is a new chemical entity and a member of a class of compounds known as nitroimidazooxazines. A successful outcome has been reported in 95 of the first 107 patients in trial after six months of treatment with this regimen and six months of post-treatment follow-up. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 16, 2019 Category: Consumer Health News Source Type: news

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. "The threat of antimicrobial-resistant infections is a key challenge we face as a public health agency," said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. (Source: World Pharma News)
Source: World Pharma News - August 15, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Pretomanid Approved for Treatment of Drug-Resistant TB
WEDNESDAY, Aug. 14, 2019 -- Pretomanid tablets in combination with bedaquiline and linezolid have been approved for the treatment of a highly treatment-resistant type of pulmonary tuberculosis (TB), the U.S. Food and Drug Administration announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 14, 2019 Category: General Medicine Source Type: news

Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ® (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - August 9, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Accelerated Approval for Sirturo (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
TITUSVILLE, NJ, August 9, 2019— The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for Sirturo (bedaquiline) tablets as part of combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 9, 2019 Category: Drugs & Pharmacology Source Type: news

Subcellular antibiotic visualization reveals a dynamic drug reservoir in infected macrophages
Tuberculosis, caused by the intracellular pathogen Mycobacterium tuberculosis, remains the world’s deadliest infectious disease. Sterilizing chemotherapy requires at least 6 months of multidrug therapy. Difficulty visualizing the subcellular localization of antibiotics in infected host cells means that it is unclear whether antibiotics penetrate all mycobacteria-containing compartments in the cell. Here, we combined correlated light, electron, and ion microscopy to image the distribution of bedaquiline in infected human macrophages at submicrometer resolution. Bedaquiline accumulated primarily in host cell lipid drop...
Source: ScienceNOW - June 27, 2019 Category: Science Authors: Greenwood, D. J., Dos Santos, M. S., Huang, S., Russell, M. R. G., Collinson, L. M., MacRae, J. I., West, A., Jiang, H., Gutierrez, M. G. Tags: Cell Biology reports Source Type: news

Outcomes of Bedaquiline Treatment in Multidrug-Resistant TB Outcomes of Bedaquiline Treatment in Multidrug-Resistant TB
What do we know about the treatment success rate of bedaquiline in multidrug-resistant tuberculosis?Emerging Infectious Diseases (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 7, 2019 Category: Infectious Diseases Tags: Infectious Diseases Journal Article Source Type: news

Stellenbosch University researchers study resistance to 'protect' anti-TB drug
(Stellenbosch University) Scientists from Stellenbosch University are trying to conserve the life-saving treatment bedaquiline, by studying how the bacterium that causes TB can develop resistance to this drug. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 30, 2019 Category: Infectious Diseases Source Type: news

Researchers identify faster, more effective drug combination regimens to treat tuberculosis
Tuberculosis is a potentially deadly though curable disease. Each year about 10 million people develop active cases, and 1.6 million people die. In addition, about 1.7 billion people around the world are infected with TB bacteria, which can lie dormant for weeks to years, then become active and cause disease in up to 10 percent of those who are infected.Today, people who contract tuberculosis typically take a course of drugs for six to eight months. However, the length of treatment means some patients don ’t stick with the therapy or may develop adverse effects from drug toxicity. Some may develop resistance to the d...
Source: UCLA Newsroom: Health Sciences - May 13, 2019 Category: Universities & Medical Training Source Type: news

Two TB survivors fight Johnson & Johnson monopoly bid
At present, only 2% of over 1.47 lakh patients suffering from multi drug resistant TB in India are currently getting Bedaquiline. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 9, 2019 Category: Pharmaceuticals Source Type: news

Tuberculosis CURED in 90% of cases with new drug hailed by doctors as 'game changer'
Doctors in Belarus tested the method, which uses the drug bedaquiline with other antibiotics, on 168 patients. The country has one of the highest rates of multidrug-resistant tuberculosis in the world. (Source: the Mail online | Health)
Source: the Mail online | Health - October 24, 2018 Category: Consumer Health News Source Type: news

Price of J & J ’s TB drug to drop by more than half
Life-saving drug bedaquiline by US pharma company Johnson& Johnson (J&J) is now being offered at $400 per patient —over 50% cheaper than the earlier price of $900. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 21, 2018 Category: Pharmaceuticals Source Type: news

World Health Organization recommends the use of bedaquiline in all conventional multidrug-resistant tuberculosis treatment regimens
(Source: Johnson and Johnson)
Source: Johnson and Johnson - August 20, 2018 Category: Pharmaceuticals Source Type: news